How Genzyme created the critical elements of #orphandrug success #raredisease

In Uncategorized by Matt Turner

David Meeker, Genzyme, orphan drug congress, rare diseasesPossibly the most significant announcement in the orphan drug and rare disease industry in 2011 was Paris based pharmaceutical giant Sanofi’s acquisition of Genzyme, a pioneer in the field of rare disease research. In 2011, the World Orphan Drug Congress was privileged to welcome the newly announced Chief Executive Officer of Genzyme, David Meeker to deliver an opening keynote to the industry on the critical elements required to achieve orphan drug success.

More than just the technical development challenges, Dr Meeker emphasised the importance of how different organisational cultures and sizes view being successful in the rare disease market and how alliances should be formed to achieve success and also following proof of orphan drug development.

Dr Meeker also rounded of his presentation by offering his take on what the take home messages are for achieving market access, creating successful clinical trials and interacting with the disease patient group?



If you found that video insightful, we have plenty more soon to be offered on the blog:

Hear a real life example of a biotech orphan drug developer’s experience of gaining regulatory approval